Don’t let the high cost of brand once-daily VMAT2 inhibitor therapy disrupt your treatment. Eligible patients may be able to access Austedo XR through the manufacturer’s Patient Assistance Program. Our advocacy service fee is $69.95 per month.
The Austedo Patient Assistance Program is run by the Teva Cares Foundation and provides Austedo and Austedo XR at no medication cost to qualifying patients — generally for up to 12 months per enrollment, with annual re-enrollment. Eligibility covers household incomes at or below 300% of the Federal Poverty Level, and Medicare Part D enrollees can qualify (patients under 150% of poverty are first asked for proof of denial from Medicare’s Extra Help subsidy — a paperwork step that trips up many applications). Applying directly (1-877-237-4881, Mon–Fri 9 AM–8 PM ET) is always free. The hard part is everything around the form: income documentation, the Extra Help denial letter where required, neurologist or psychiatrist coordination, prior-authorization records, dose-titration timing, denial appeals, and renewal deadlines. For a flat $69.95 per month, our Patient Advocates handle every step — from initial application through refills and re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$11,200 | Save ~$11,130/mo |
| CVS Pharmacy | ~$11,500 | Save ~$11,430/mo |
| Walmart | ~$9,500 | Save ~$9,430/mo |
| Costco | ~$9,300 | Save ~$9,230/mo |
Specialty Pharmacy | ~$9,800 | Save ~$9,730/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Teva Cares program is free to apply for and provides Austedo at no medication cost if approved. Our $69.95/month service covers full advocacy — for patients who want an experienced team managing the process end-to-end, including the Extra Help denial-letter step that derails many Medicare applications.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Austedo XR:
Still $9,000–$11,500 per month even with the best discount
The Teva Cares Foundation publishes clear eligibility rules for free Austedo. You will generally qualify if all of the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Austedo assistance:
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Austedo (deutetrabenazine) is a VMAT2 inhibitor that smooths out the excess dopamine signaling behind the involuntary movements of tardive dyskinesia and Huntington’s disease chorea — without requiring patients to stop the psychiatric medications they depend on.
How Austedo Works:
Tardive dyskinesia typically develops after long-term use of dopamine-blocking medications, which leave movement circuits hypersensitive. Deutetrabenazine inhibits VMAT2, the transporter that packages dopamine for release, reducing the surplus signaling that drives involuntary movements. Its distinguishing chemistry — deuterium atoms replacing hydrogen — slows the drug’s breakdown, allowing steadier blood levels with fewer daily peaks and troughs than older tetrabenazine.
Form and Use:
Since 2024, Austedo XR covers all therapeutic doses (24, 30, 36, 42, and 48 mg) as one pill, once daily — replacing the twice-daily regimens that made adherence harder. Treatment starts low and titrates up over weeks, which matters for cost planning: your dose (and Teva’s dose-based pricing) will likely change during the first months, and assistance enrollment should be in place before titration starts, not after the first big pharmacy bill.
Generic Availability:
There is no generic deutetrabenazine in the U.S. Teva’s patent settlements license generic entry beginning around April 2033. The alternative VMAT2 inhibitor, Ingrezza (valbenazine), is a different drug with different dosing — an alternative to discuss with your prescriber, not a generic substitute. For most patients, assistance programs are the affordability plan for years to come.
Warnings:
Austedo carries boxed warnings for depression and suicidality in patients with Huntington’s disease — mood must be monitored, and any new depression or suicidal thoughts reported immediately. It can prolong the QT interval at higher doses and interacts with strong CYP2D6 inhibitors (including fluoxetine and paroxetine), MAOIs, and reserpine. Common effects include somnolence, diarrhea, dry mouth, and fatigue. Do not stop abruptly without your prescriber’s guidance.
Teva’s published list prices run from $2,501.50 (6 mg) to $15,008.90 (48 mg) per month — roughly $10,000 monthly at the common 24 mg therapeutic dose. Eligible patients can receive Austedo free through the Teva Cares Foundation; our $69.95 monthly fee covers full advocacy and enrollment management.
Tardive dyskinesia (TD) is a movement disorder — repetitive, involuntary movements often of the face, tongue, or limbs — that can develop after long-term use of dopamine-blocking medications such as antipsychotics. Austedo was among the first FDA-approved treatments, and patients typically continue their psychiatric medication alongside it.
Yes — under Part D. The $2,100 annual out-of-pocket cap (2026) limits total drug spending, Extra Help enrollees pay about $12.15 per month, and Teva Cares accepts Part D patients within its 300%-FPL income limits — though under-150%-FPL applicants must first show an Extra Help denial letter, a step we handle routinely.
No — the copay program excludes all government insurance and even Medicare-eligible patients on employer retiree plans. Medicare patients rely on the Part D cap, Extra Help, or Teva Cares.
No — patent settlements keep generic deutetrabenazine off the U.S. market until around 2033. Ingrezza is an alternative VMAT2 inhibitor, not a generic equivalent.
? Denials are usually about documentation — missing income proof, a missing Extra Help denial letter, or incomplete prescriber sections. Applications can be corrected and resubmitted. We review the denial letter, fix what triggered it, and resubmit on your behalf
Teva says more than 90% of Austedo patients pay $10 or less — the gap between that number and a $10,000 list price is entirely about being enrolled in the right program. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.